Results 51 to 60 of about 3,996,555 (297)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Ruptured metastatic pleuropulmonary blastoma simulating cerebral hemorrhage

Reports of Practical Oncology and Radiotherapy
None.
Aleksandra Osińska, Claudia Sieńko, Milena Kędra, Andrzej Materniak, Magdalena M. Woźniak   +4 more
doaj   +1 more source

Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases

Radiation Oncology, 2021
Background The management of melanoma with brain metastases (MBM) is increasingly complex, especially given recent improvements in targeted agents, immunotherapy, and radiotherapy.
Cecilia Jiang, Troy J. Kleber, Jeffrey M. Switchenko, Mohammad K. Khan   +3 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial [PDF]

Background : Stereotactic radiotherapy (SRT) is an attractive treatment option for patients with brain metastases (BM), sparing healthy brain tissue and likely controlling local tumors.
Bruynzeel, Anna, Eekers, Danielle, Hurkmans, Coen, Swaak-Kragten, Annemarie, Verhoeff, Joost J.C., Wiggenraad, Ruud, Swinnen, Ans, Dieleman, Edith, van der Toorn, Peter Paul, van Veelen, Lieneke, Hartgerink, Dianne, Lambin, Philippe, Zindler, Jaap, de Ruysscher, Dirk, Lagerwaard, Frank   +14 more
core   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Dosimetric Comparison between Simultaneous Integrated Boost Dynamic Conformal Arc Therapy and Whole Brain Radiation Therapy Techniques in Treatment of Patients with Multiple Brain Metastases [PDF]

Egyptian Journal of Cancer and Biomedical Research
Background: Whole Our study aims to compare between the dosimetric results and treatment delivery efficiency of Whole Brain Radiation Therapy (WBRT) versus Simultaneous Integrated Boost Dynamic Conformal Arc Therapy (DCAT) planning techniques – to ...
Ahmed ElDrieny, Ahmed Ahmed, Nayera Mahmoud, Azza Darwish   +3 more
doaj   +1 more source

Palliative care in patients who receive whole brain radiotherapy for brain metastases in Ahmadu Bello University Teaching Hospital, Zaria [PDF]

, 2016
Background: Brain Metastases is a devastating complication of Cancer affecting 10-50% of patients with systemic disease. It by far outnumbers primary Brain tumor in a 10:1 ratio.Aims and Objective: To determine the age distribution, gender distribution ...
Adamu, A, Chukwuocha, I.C., Olasinde, T.A., Jimeta, J.D.   +3 more
core   +1 more source

Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control [PDF]

, 2022
PURPOSE: Does focal cavity radiotherapy after resection of brain metastasis “spare” whole-brain radiotherapy, which is associated with toxicity for patients, through the complete course of their disease without compromising long-term local control of the
Berlis, Ansgar, Kahl, Klaus-Henning, Janzen, Tilman, Maurer, Christoph J., Shiban, Ehab, Müller, Heiko, Kahl, Klaus Henning, Sommer, Björn, Grossert, Ute, Gutser, Susanne, Konietzko, Ina, Stüben, Georg   +11 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source